HGH 191aa
HGH 191aa (Somatropin, Human Growth Hormone 191 amino acids) is a recombinant form of human growth hormone identical to the native pituitary-derived hormone. Preclinical studies in cell cultures and animal models indicate that HGH 191aa binds to the GH receptor, activates the JAK-STAT pathway, stimulates IGF-1 production in the liver, and promotes anabolic effects on protein synthesis, lipolysis, and tissue growth.[1][2]
Key Research Areas
- Growth & Anabolic Effects – In rodent and primate models of growth hormone deficiency, HGH 191aa has been shown to increase linear growth, enhance muscle mass, and promote protein accretion through IGF-1-mediated signaling.[3][4]
- Lipolysis & Metabolic Regulation – Preclinical investigations demonstrate HGH 191aa stimulates fat mobilization, reduces adiposity, and improves lipid profiles in models of obesity and metabolic syndrome.[5][6]
- Tissue Repair & Recovery Pathways – Animal studies suggest HGH 191aa supports collagen synthesis, cartilage maintenance, and wound healing in models of injury, aging, and connective tissue damage.[7][8]
Product Specifications
| CAS Number |
12629-01-5 |
| Molecular Formula |
C990H1529N263O299S7 |
| Molar Mass |
22124.12 g/mol (approximate) |
| Sequence |
Full 191 amino acid sequence (recombinant human somatropin): Phe-Pro-Thr-Ile-Pro-Leu-Ser-Arg-Leu-Phe-Asp-Asn-Ala-Met-Leu-Arg-Ala-His-Arg-Leu-His-Gln-Leu-Ala-Phe-Asp-Thr-Tyr-Gln-Glu-Phe-Glu-Glu-Ala-Tyr-Ile-Pro-Lys-Glu-Gln-Lys-Tyr-Ser-Phe-Leu-Gln-Asn-Pro-Gln-Thr-Ser-Leu-Cys-Phe-Ser-Glu-Ser-Ile-Pro-Thr-Pro-Ser-Asn-Arg-Glu-Glu-Thr-Gln-Gln-Lys-Ser-Asn-Leu-Glu-Leu-Leu-Arg-Ile-Ser-Leu-Leu-Leu-Ile-Gln-Ser-Trp-Leu-Glu-Pro-Val-Gln-Phe-Leu-Arg-Ser-Val-Phe-Ala-Asn-Ser-Leu-Val-Tyr-Gly-Ala-Ser-Asp-Ser-Asn-Val-Tyr-Asp-Leu-Leu-Lys-Asp-Leu-Glu-Glu-Gly-Ile-Gln-Thr-Leu-Met-Gly-Arg-Leu-Glu-Asp-Gly-Ser-Pro-Arg-Thr-Gly-Gln-Ile-Phe-Lys-Gln-Thr-Tyr-Ser-Lys-Phe-Asp-Thr-Asn-Ser-His-Asn-Asp-Asp-Ala-Leu-Leu-Lys-Asn-Tyr-Gly-Leu-Leu-Tyr-Cys-Phe-Arg-Lys-Asp-Met-Asp-Lys-Val-Glu-Thr-Phe-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe |
| Synonyms |
Somatropin, Recombinant Human Growth Hormone, rhGH, 191aa HGH |
| Purity |
≥99% (HPLC) |
| Form |
Lyophilized powder |
| Storage |
−20°C (long-term), 2–8°C (reconstituted) |
| Solubility |
Bacteriostatic water or sterile saline for reconstitution |
References
- 1. Kopchick JJ, et al. Growth hormone receptor antagonists: discovery and potential therapeutic uses. Endocr Rev. 2000. PubMed
- 2. Baumann G. Growth hormone heterogeneity: genes, isohormones, variants, and binding proteins. Endocr Rev. 1991. PubMed
- 3. Clark RG, et al. Effects of recombinant human growth hormone on growth in rats. J Endocrinol. 1987. PubMed
- 4. Skottner A, et al. Growth promoting effects of recombinant human growth hormone in hypophysectomized rats. Acta Paediatr Scand Suppl. 1986. PubMed
- 5. Jorgensen JO, et al. Effects of growth hormone on body composition in adults with growth hormone deficiency. Acta Endocrinol (Copenh). 1989. PubMed
- 6. Rudman D, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med. 1990. PubMed
- 7. Velloso CP, et al. Growth hormone action in skeletal muscle. Endocr Rev. 2001. PubMed
- 8. Laron Z. Growth hormone insensitivity (Laron syndrome). Recent Prog Horm Res. 1993. PubMed
All products offered by Premier Research are intended for laboratory research use only. These materials are not for human or veterinary consumption, medical use, diagnostic procedures, or therapeutic applications. Statements on this website are for informational and educational purposes only and have not been evaluated by the U.S. Food and Drug Administration (FDA). By accessing this site, you confirm that you are a qualified researcher or institution representative and agree to use all materials in accordance with applicable laws, regulations, and safety guidelines.
